Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 44HER2-positive Breast Cancer 8Carcinoma, Non-Small-Cell Lung 5Breast Diseases 3Brain Neoplasms 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Rare Tumour 1Rare Tumor 1Pathologic Complete Response 1Non Small Cell Lung 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1Metastatic Breast Cancer in the Brain 1Lung Neoplasms 1HER2-positive Metastatic Breast Cancer 1HER2-positive Early Breast Cancer 1HER2+ Early or Locally Advanced Breast Cancer 1HER2 Positive Metastatic Breast Cancer 1HER2 Positive Breast Cancer 1HER2 Insertion Mutation Positive Advanced NSCLC 1Estrogen Receptor-positive Breast Cancer 1Esophageal Squamous Cell Carcinoma 1Digestive System Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Breast Cancer Invasive 1

Interventions

apatinib 3vistusertib 2olaparib 2camrelizumab 2atezolizumab 2Ipilimumab 2Everolimus 2trametinib 1toripalimab 1tilsotolimod 1tazemetostat 1tazarotene 1spartalizumab 1seviteronel 1sargramostim 1sacituzumab govitecan 1rucaparib 1roniciclib 1romiplostim 1pyrotinib 1phosphorylethanolamine 1pemigatinib 1pembrolizumab 1pazopanib 1palbociclib 1niraparib 1magrolimab 1lenvatinib 1irinotecan sucrosofate 1famitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Solid Tumor × pyrotinib × Clear all
NCT04179656 2019-11-27

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Tianjin Medical University Second Hospital

Phase 2 Unknown
100 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡